Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kensey Nash

This article was originally published in The Gray Sheet

Executive Summary

Proposed secondary offering of 3.2 mil. shares of common stock includes 2.5 mil. shares to be offered by the company and 700,000 shares to be offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds will also be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group is lead manager of the offering; PaineWebber and Warburg Dillon Read will act as co-managers

You may also be interested in...

Kensey Nash Evaluating Aegis Vortex Atherectomy System In Pilot Study

Kensey Nash's recently initiated pilot study for its Aegis Vortex System (AVS) for treating occluded saphenous vein grafts is designed to support FDA approval for an estimated 300-patient pivotal trial.

Start-Up Snapshot: Nanomedic’s Electro-spinning, Portable Wound Care Device

At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.

Start-Up Snapshot: Sweetch, Automated AI Wellness Management

At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts